WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments ...

NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic ...

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S.

NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications and Galderma, a worldwide specialty ...

Collaborative partnerships can foster success in formulation development projects. The formulation development outsourcing market is expected to grow at a compound annual rate of 7.2% between 2021 and ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...

Foam is for more than just bubble baths — an Israeli medical development firm has found dozens of beneficial uses. One of the most promising is an acne treatment that researchers say is more effective ...

Insights into molecular behaviors and predictive capabilities are bringing numerous benefits. The potential benefits afforded by molecular modeling when applied to formulation development are, in fact ...

In the ever-evolving world of pharmaceutical development, the quest to innovate and improve the delivery of drug substances remains a top priority. Among the many formulation strategies, oral liquid ...

The global formulation development outsourcing market is on a significant growth trajectory, with a projected compound annual growth rate (CAGR) of 7.2% over the next decade. Valued at USD 33.23 ...